

Triple Negative Breast Cancer: An Evolving Treatment Landscape

**Sunday,
11 September 2022**
18:30 – 20:00 (CEST)

7.3.Q – Quimper Auditorium, Hall 7, Level 7.3
Paris Expo Porte de Versailles
Paris, France

Chair



Hope S. Rugo
Professor
Department of Medicine
(Hematology/Oncology)
Director
Breast Oncology and
Clinical Trials Education
UCSF
San Francisco, CA, USA

Faculty



Rupert Bartsch
Associate Professor
Medical University of Vienna
Consultant
Medical Oncology
Department of Medicine I
Clinical Division of Oncology
Medical University of Vienna
Vienna, Austria



Peter Schmid
Clinical Director
Breast Cancer Center
Barts Health NHS Trust
St. Bartholomew's Hospital
London, England



Giuseppe Viale
Director
Department of Pathology and
Laboratory Medicine
Division of Pathology
European Institute of Oncology (IEO)
University of Milan
Milan, Italy

Agenda

18:30 – 18:35	Introductions and objectives <i>Hope S. Rugo</i>
18:35 – 18:55	Review of the evolving treatment landscape in early TNBC <i>Peter Schmid</i>
18:55 – 19:15	Review of the evolving treatment landscape in metastatic TNBC <i>Rupert Bartsch</i>
19:15 – 19:35	PD-L1 testing for metastatic TNBC <i>Giuseppe Viale</i>
19:35 – 19:45	Breast cancer patient case study <i>Hope S. Rugo</i>
19:45 – 19:55	Q&A from audience <i>Moderated by Hope S. Rugo</i>
19:55 – 20:00	Closing remarks <i>Hope S. Rugo</i>

Agenda may be subject to change pending speaker confirmation